Analysts expect Natus Medical Incorporated (NASDAQ:BABY) to report sales of $130.61 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Natus Medical’s earnings, with estimates ranging from $130.40 million to $130.80 million. Natus Medical reported sales of $122.23 million in the same quarter last year, which indicates a positive year over year growth rate of 6.9%. The company is expected to report its next earnings report on Wednesday, July 25th.
According to Zacks, analysts expect that Natus Medical will report full-year sales of $537.36 million for the current year, with estimates ranging from $536.30 million to $538.18 million. For the next financial year, analysts expect that the firm will report sales of $557.44 million per share, with estimates ranging from $546.90 million to $566.63 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Natus Medical.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, April 25th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.24. The firm had revenue of $128.60 million during the quarter, compared to analysts’ expectations of $125.91 million. Natus Medical had a positive return on equity of 10.96% and a negative net margin of 4.71%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.30 earnings per share.
A number of research firms recently issued reports on BABY. BidaskClub raised Natus Medical from a “hold” rating to a “buy” rating in a research report on Saturday, April 21st. Zacks Investment Research raised Natus Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 10th. ValuEngine cut Natus Medical from a “hold” rating to a “sell” rating in a research report on Thursday, May 3rd. Roth Capital set a $39.00 price objective on Natus Medical and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, Benchmark reissued a “buy” rating and set a $49.00 price objective (down previously from $55.00) on shares of Natus Medical in a research report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Natus Medical presently has a consensus rating of “Hold” and an average target price of $44.33.
BABY traded up $0.90 during trading on Friday, reaching $35.05. 200,262 shares of the stock traded hands, compared to its average volume of 279,494. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of 24.17 and a beta of 0.49. Natus Medical has a fifty-two week low of $34.20 and a fifty-two week high of $35.20. The company has a current ratio of 3.06, a quick ratio of 2.28 and a debt-to-equity ratio of 0.31.
Natus Medical declared that its board has authorized a stock buyback plan on Thursday, February 22nd that authorizes the company to buyback $30.00 million in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.
In other Natus Medical news, Director Ken Ludlum sold 4,000 shares of the firm’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $31.68, for a total transaction of $126,720.00. Following the transaction, the director now directly owns 93,825 shares in the company, valued at $2,972,376. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider James B. Hawkins sold 160,000 shares of the firm’s stock in a transaction dated Monday, April 30th. The shares were sold at an average price of $33.47, for a total value of $5,355,200.00. Following the transaction, the insider now owns 686,757 shares in the company, valued at $22,985,756.79. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 179,358 shares of company stock worth $5,993,649. Corporate insiders own 5.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Natus Medical by 7.3% in the first quarter. BlackRock Inc. now owns 4,326,763 shares of the medical equipment provider’s stock worth $145,597,000 after purchasing an additional 294,082 shares during the period. Eagle Asset Management Inc. grew its position in Natus Medical by 29.8% during the first quarter. Eagle Asset Management Inc. now owns 519,880 shares of the medical equipment provider’s stock worth $17,493,000 after buying an additional 119,495 shares in the last quarter. Lyon Street Capital LLC boosted its holdings in Natus Medical by 17.3% during the fourth quarter. Lyon Street Capital LLC now owns 343,645 shares of the medical equipment provider’s stock valued at $13,127,000 after purchasing an additional 50,748 shares in the last quarter. Millennium Management LLC acquired a new stake in Natus Medical during the fourth quarter valued at approximately $10,445,000. Finally, WCM Investment Management CA boosted its holdings in Natus Medical by 503.8% during the fourth quarter. WCM Investment Management CA now owns 267,850 shares of the medical equipment provider’s stock valued at $10,232,000 after purchasing an additional 223,490 shares in the last quarter. Institutional investors and hedge funds own 95.88% of the company’s stock.
Natus Medical Company Profile
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Get a free copy of the Zacks research report on Natus Medical (BABY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.